Uric acid-induced pancreatic β-cell dysfunction

BMC Endocr Disord. 2021 Feb 16;21(1):24. doi: 10.1186/s12902-021-00698-6.

Abstract

Hyperuricemia is associated with insulin resistance, pancreatic β-cell dysfunction and consequently with development of type 2 diabetes. Although a direct relationship between high levels of uric acid (UA) and the development of diabetes is still a controversial issue, there is some evidence that strongly points to pancreatic β-cells damage as a result of high serum UA levels. Here, the mechanisms underlying UA-induced β-cell damage are discussed. Available literature indicates that UA can decrease glucose-stimulated insulin secretion and cause β-cell death. The mechanisms underlying these effects are UA-induced oxidative stress and inflammation within the β-cells. UA also stimulates inducible nitric oxide (NO) synthase (iNOS) gene expression leading to NO-induced β-cell dysfunction. Thus hyperuricemia may potentially cause β-cell dysfunction, leading to diabetes. It may be hypothesized that in hyperuricemic subjects, UA-lowering drugs may be beneficial in preventing diabetes.

Keywords: Nitric oxide; Pancreatic β-cell; Type 2 diabetes; Uric acid.

Publication types

  • Review

MeSH terms

  • Animals
  • Cell Death
  • Diabetes Mellitus, Type 2 / etiology*
  • Diabetes Mellitus, Type 2 / prevention & control
  • Humans
  • Hyperuricemia / complications*
  • Hyperuricemia / drug therapy
  • Insulin Secretion
  • Insulin-Secreting Cells / metabolism*
  • Nitric Oxide / blood
  • Uric Acid / metabolism*
  • Uricosuric Agents / therapeutic use

Substances

  • Uricosuric Agents
  • Uric Acid
  • Nitric Oxide